UHS trades 6.4% below Wall Street's consensus target of $193.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes UHS achieves its forward estimates and maintains a stable P/E multiple of 8.1x. This scenario reflects the blended consensus of 43 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, Universal Health Services, Inc. (UHS) has a Wall Street consensus price target of $193.00, based on estimates from 43 covering analysts. With the stock currently trading at $181.39, this represents a potential upside of +6.4%. The company has a market capitalization of $10.98B.
Analyst price targets range from a low of $166.00 to a high of $290.00, representing a 64% spread in expectations. The median target of $189.00 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Hold, with 16 analysts rating the stock as a Buy or Strong Buy,25 rating it Hold, and 2 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, UHS trades at a trailing P/E of 7.9x and forward P/E of 8.1x. The forward PEG ratio of 0.50 suggests the stock may be undervalued relative to its growth. Analysts expect EPS to grow -11.5% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $212.61, with bear and bull scenarios of $133.94 and $280.13 respectively. Model confidence stands at 65/100, reflecting moderate uncertainty in projections.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 HCAHCA Healthcare, Inc. | $94.5B | $436.48 | $455.19 | +4.3% | Buy | 14.8x | 46 |
 THCTenet Healthcare Corporation | $22.1B | $256.44 | $284.77 | +11.0% | Buy | 12.1x | 32 |
 CYHCommunity Health Systems, Inc. | $424M | $3.01 | $2.92 | -3.0% | Hold | — | 37 |
 ENSGThe Ensign Group, Inc. | $10.2B | $175.46 | $215.00 | +22.5% | Buy | 22.5x | 13 |
 ACHCAcadia Healthcare Company, Inc. | $2.7B | $28.51 | $34.43 | +20.8% | Buy | 18.7x | 25 |
 SEMSelect Medical Holdings Corporation | $2.0B | $16.51 | $16.50 | -0.1% | Hold | 13.5x | 14 |
 SGRYSurgery Partners, Inc. | $1.9B | $14.56 | $18.00 | +23.6% | Buy | 31.8x | 22 |
 USPHU.S. Physical Therapy, Inc. | $1.3B | $82.65 | $90.00 | +8.9% | Buy | 30.0x | 13 |
 PRAAPRA Group, Inc. | $767M | $20.11 | $25.00 | +24.3% | Hold | 6.0x | 13 |
 UNHUnitedHealth Group Incorporated | $337.2B | $371.29 | $473.89 | +27.6% | Buy | 18.7x | 52 |
Quick answers to the most common questions about buying UHS stock.
The consensus price target for UHS is $193, close to the current price of $181.39 (6.4% implied move). Based on 43 analyst estimates, the stock appears fairly valued near current levels.
UHS has a consensus rating of "Hold" based on 43 Wall Street analysts. The rating breakdown is mixed, with 25 Hold ratings making up the largest segment. The consensus 12-month price target of $193 implies 6.4% upside from current levels.
With a forward P/E of 8.0516x, UHS trades at a relatively low valuation. The consensus target of $193 implies 6.4% appreciation, suggesting the market may be pricing in risks.
The most bullish Wall Street analyst has a price target of $290 for UHS, while the most conservative target is $166. The consensus of $193 represents the median expectation. Our quantitative valuation model projects a bull case target of $280 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
UHS is heavily covered by Wall Street, with 43 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 16 have Buy ratings, 25 recommend Hold, and 2 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month UHS stock forecast based on 43 Wall Street analysts shows a consensus price target of $193, with estimates ranging from $166 (bear case) to $290 (bull case). The median consensus rating is "Hold". Our proprietary valuation model produces a base case fair value of $213, with bear/bull scenarios of $134/$280.
Our quantitative valuation model calculates UHS's fair value at $213 (base case), with a bear case of $134 and bull case of $280. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 65/100.
UHS trades at a forward P/E ratio of 8.1x based on next-twelve-months earnings estimates compared to a trailing P/E of 7.9x. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
UHS appears fairly valued according to analysts, with a "Hold" rating and minimal upside to the $193 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
UHS analyst price targets range from $166 to $290, a 64% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $193 consensus represents the middle ground. Our model's $134-$280 range provides an independent fundamental perspective.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.